Two mechanistic oncology studies mapped complementary ways to reshape tumor immunity. A Nature Communications paper dissected how germline and somatic variation in complement cascade genes influences pancreatic cancer susceptibility and prognosis, implicating complement components in tumor‑microenvironment remodeling. Separately, researchers showed that pharmacologic or genetic blockade of TBK1 and IKKε kinases enhances immune‑mediated tumor cell killing by modulating innate signaling pathways. The paired findings point to both complement modulation and TBK1/IKKε inhibition as actionable strategies to sensitize resistant tumors to immune clearance.